<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02148146</url>
  </required_header>
  <id_info>
    <org_study_id>105591</org_study_id>
    <nct_id>NCT02148146</nct_id>
  </id_info>
  <brief_title>Use of Omega 3 Oil Emulsion for Parenteral Nutrition Associated Cholestasis</brief_title>
  <official_title>Clinical Trial of Omegaven™ Therapy for Parenteral Nutrition Associated Cholestasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <brief_summary>
    <textblock>
      This is a clinical study designed to evaluate the safety and benefit of a fish oil based fat&#xD;
      emulsion in the treatment of liver disease associated with prolonged use of intravenous&#xD;
      nutrition.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific Aims of Study&#xD;
&#xD;
        1. To determine the safety profile of an intravenous omega-3 fat emulsion (Omegaven™)&#xD;
&#xD;
        2. To determine if established PN associated liver disease can be reversed or its&#xD;
           progression halted by using a parenteral fat emulsion prepared from fish oil as measured&#xD;
           by normalization of serum levels of hepatic enzymes and bilirubin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>Cholestasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omegaven</intervention_name>
    <description>Fish oil emulsion given 1g/kg/day as infusion</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &lt; 18 years old&#xD;
&#xD;
          2. Patients will be PN dependent (unable to meet nutritional needs solely by enteral&#xD;
             nutrition) and are expected to require PN for at least another 30 days, may be&#xD;
             inpatient or outpatient&#xD;
&#xD;
          3. Patients considered eligible for study participation must have parenteral nutrition&#xD;
             associated liver disease (PNALD) as defined as a direct bilirubin of 2 mg/dl or more.&#xD;
             Other causes of liver disease should be excluded. A liver biopsy is not necessary for&#xD;
             treatment&#xD;
&#xD;
          4. Direct bilirubin &gt; 2.0 mg/dl&#xD;
&#xD;
          5. Signed patient informed consent&#xD;
&#xD;
          6. The patient must have utilized standard therapies to prevent the progression of&#xD;
             his/her liver disease including surgical treatment, cyclic PN, avoiding overfeeding,&#xD;
             reduction/removal of copper and manganese from PN, advancement of enteral feeding, or&#xD;
             the use of ursodiol (i.e., Actigall®)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy&#xD;
&#xD;
          2. Other causes of chronic liver disease (Hepatitis C, Cystic fibrosis, biliary atresia,&#xD;
             and alpha 1 anti-trypsin deficiency)&#xD;
&#xD;
          3. Enrollment in any other clinical trial involving an investigational agent (unless&#xD;
             approved by the designated physicians on the multidisciplinary team)&#xD;
&#xD;
          4. The parent or guardian or child unwilling to provide consent or assent&#xD;
&#xD;
          5. Patients known to be allergic to fish or egg protein and patients with the following&#xD;
             contraindications to Omegaven™ use:&#xD;
&#xD;
               -  Impaired lipid metabolism&#xD;
&#xD;
               -  Severe hemorrhagic disorders&#xD;
&#xD;
               -  Unstable diabetes mellitus&#xD;
&#xD;
               -  Collapse and shock&#xD;
&#xD;
               -  Stroke/embolism&#xD;
&#xD;
               -  Recent cardiac infarction&#xD;
&#xD;
               -  Undefined coma status&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah Lazar, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>UC San Diego Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UC San Diego Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital of San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 20, 2014</study_first_submitted>
  <study_first_submitted_qc>May 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2014</study_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>short bowel syndrome</keyword>
  <keyword>intestinal failure</keyword>
  <keyword>total parenteral nutrition associated cholestasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholestasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

